[Translation] A multicenter, open-label, dose-escalation and dose-expansion Phase I clinical study to evaluate the safety, pharmacokinetics and anti-tumor activity of HC010 in patients with advanced solid tumors
主要目的:
评估HC010在晚期实体瘤患者中的安全性和耐受性。
次要目的:
1. 评估HC010在晚期实体瘤患者中的药代动力学(PK)特征。
2. 评估HC010在晚期实体瘤患者中的免疫原性。
3. 初步评估HC010在晚期实体瘤患者中的抗肿瘤活性。
[Translation] Primary objectives:
To evaluate the safety and tolerability of HC010 in patients with advanced solid tumors.
Secondary objectives:
1. To evaluate the pharmacokinetic (PK) characteristics of HC010 in patients with advanced solid tumors.
2. To evaluate the immunogenicity of HC010 in patients with advanced solid tumors.
3. To preliminarily evaluate the anti-tumor activity of HC010 in patients with advanced solid tumors.